Premium
Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin‐1 stimulatory effects
Author(s) -
El-Mowafy Abdalla M.,
White Richard E.
Publication year - 1999
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)00541-4
Subject(s) - mapk/erk pathway , phosphorylation , medicine , endocrinology , chemistry , tyrosine phosphorylation , protein kinase a , p38 mitogen activated protein kinases , estrogen receptor , biology , microbiology and biotechnology , cancer , breast cancer
In porcine coronary arteries, short‐term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC 50 =37 μM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK‐1/‐2, JNK‐1 and p38, at active sites. Endothelin‐1 (ET‐1), a primary antecedent in coronary heart diseases, enhanced MAPK activity, phosphorylation and nuclear translocation in a concentration‐responsive but RSVL‐sensitive manner. RSVL had no effect on basal or forskolin‐stimulated cAMP levels, a known downregulator of the MAPK cascade. Likewise, inhibition of MAPK by RSVL was not reversed by the estrogen receptor blockers tamoxifen and ICI‐182,780. Conversely, RSVL remarkably attenuated basal and ET‐1‐evoked protein tyrosine phosphorylation. Because MAPKs promote smooth muscle proliferation and contraction, their current inhibition may contribute to the putative protection by RSVL against coronary heart diseases. These effects apparently do not involve interaction with estrogen receptors.